Avita Medical Ltd (RCEL)
Avita Medical Ltd is a healthcare company focused on therapeutic acute wound care. The company develops and commercializes the RECELL System, a cell-harvesting device used in the treatment of thermal burn wounds and full-thickness skin defects, and for repigmenting stable depigmented vitiligo lesions. Its product range also includes the RECALL autologous cell harvesting device, RECELL autologous cell harvesting devices designed for easier use, and the RECELL GO line for smaller wound areas. In addition, Avita Medical sells PermeaDerm, a biosynthetic wound matrix, and Cohealyx, a collagen-based dermal matrix. The company serves hospitals, treatment centers, and distributors across the United States, Japan, the European Union, Australia, and the United Kingdom. Headquartered in Valencia, California, it was formerly known as AVITA Therapeutics, Inc. before adopting its current name in December 2020.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Next Earnings Date | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-RCEL
|
$8.32
|
-27.6% Downside
|
Overvalued
|
$12.30
|
7.1% Upside
|
Fair
|
Fair
|
0.0%
|
November 5, 2026
|
4.7x
|
355.3 M
|
392.7 M
|
11.9%
|
98.5%
|
-13.3
|
57.1%
|
